Neutralizing antibodies against mumps and measles virus are considered a correlate of protection against these diseases. Measurement of neutralizing antibodies is mostly performed using plaque reduction neutralization assay or 50% cell culture infective dose (CCID₅₀) neutralization assay, but there are attempts for measuring neutralizing antibodies using enzyme-linked immunosorbent assay (ELISA) which is simpler, but the literature data regarding its convenience are diverse. The role of complement and antibodies in neutralizing capacity of sera is not completely defined. Here, CCID₅₀ neutralization assay and ELISA were used to determine the neutralization capacity against mumps and measles virus in human sera and therapeutic immunoglobulins (IVIGs). Results showed no correlation of neutralization titers obtained by CCID₅₀ neutralization assay and IgG content obtained by ELISA for mumps or measles in human sera. Data showed some neutralization activity against measles virus and quite high against mumps virus of naïve guinea pig serum and that its addition increases neutralization capacity of IVIG and human sera against mumps and measles viruses. Heat inactivation of human sera reduced neutralization capacity against measles to small extent, and substantially against mumps virus. There is a significant impact of complement in measurement of neutralization capacity against mumps virus.

针对腮腺炎和麻疹病毒的中和抗体被认为是预防这些疾病的相关因素。中和抗体的测量主要使用斑块减少中和试验或 50% 细胞培养感染剂量 (CCID ₅₀ ) 中和试验进行，但也有人尝试使用酶联免疫吸附试验 (ELISA) 来测量中和抗体，这是一种更简单的方法，但文献关于其便利性的数据是多种多样的。补体和抗体在血清中和能力中的作用尚未完全确定。在这里，赛迪₅₀中和试验和 ELISA 用于确定对人血清和治疗性免疫球蛋白 (IVIG) 中的腮腺炎和麻疹病毒的中和能力。结果表明，通过 CCID ₅₀中和试验获得的中和滴度与通过 ELISA 获得的人血清中腮腺炎或麻疹的 IgG 含量没有相关性。数据显示，幼稚豚鼠血清对麻疹病毒有一定的中和活性，对腮腺炎病毒具有相当高的中和活性，并且它的加入增加了 IVIG 和人血清对腮腺炎和麻疹病毒的中和能力。人血清的热灭活在较小程度上降低了对麻疹的中和能力，并在很大程度上降低了对腮腺炎病毒的中和能力。补体在测量针对腮腺炎病毒的中和能力方面有显着影响。